RPRX Royalty Pharma plc
Price Chart
Executive Summary
Royalty Pharma entered into a new $1.8B unsecured revolving credit facility on May 22, 2026, replacing its prior credit agreement. The facility matures on May 22, 2031, and carries financial covenants including a maximum consolidated leverage ratio of 4.00x (stepping to 4.50x post-qualifying acquisition), a maximum portfolio cash flow ratio of 5.00x, and a minimum coverage ratio of 2.50x. This refinancing extends Royalty Pharma's debt maturity profile and maintains ample liquidity for acquisitions and working capital.
Key Financial Metrics
Actionable Insight
This is a routine refinancing that extends debt maturity by 5 years and maintains the same $1.8B commitment size. No financial data or guidance was reported. The covenant package is standard and the step-up for qualifying acquisitions signals flexibility for dealmaking. Monitor for any material acquisition announcements that could utilize the accordion feature or trigger the higher leverage limits.
Key Facts
- Royalty Pharma entered a $1.8B unsecured revolving credit facility on May 22, 2026.
- The facility matures on May 22, 2031 (5-year term).
- The agreement refinanced and replaced the prior $1.8B facility from September 2021.
- Financial covenants include: max consolidated leverage ratio 4.00x (4.50x step-up for qualifying acquisitions), max portfolio cash flow ratio 5.00x (5.50x step-up), min coverage ratio 2.50x.
- Initial pricing is at Level 2 (BBB/BBB/Baa2) with an applicable margin of 1.125% over Term SOFR and an unused commitment fee of 0.10%.
- The facility includes an accordion feature allowing up to $900M in additional commitments.
- L/C sublimit is $100M.
- Proceeds can be used for working capital, acquisitions, and purchase of royalty assets.
Financial Impact
Refinancing of $1.8B revolving credit facility with a 5-year maturity, same size as prior facility. No new net debt created.
Risk Factors
- Leverage could increase if the company funds large acquisitions, though the step-up covenants provide buffer.
- Uncertainty around future interest rates could impact borrowing costs on drawn amounts.
- No financial performance data was provided in this filing to assess current credit metrics.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-245163 |
| Document: d131735d8k.htm | 0001193125-26-245163 |
| Document: 0001193125-26-245163-index-headers.html | 0001193125-26-245163 |
| Document: 0001193125-26-245163-index.html | 0001193125-26-245163 |
| Document: 0001193125-26-245163.txt | 0001193125-26-245163 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
15d ago
|
Insider Cluster
| $55.76 $55.87 | ▲ +0.20% | ▲ +2.72% | $54.87 (−1.60%) |
|
May 28, 2026
15d ago
|
8-K
| $55.76 $54.97 | ▼ −1.42% | ▼ −1.12% | $54.87 (−1.60%) |
|
May 22, 2026
22d ago
|
Insider Cluster
| $54.50 $55.18 | ▲ +1.25% | ▼ −0.41% | $54.87 (+0.68%) |
|
May 15, 2026
28d ago
|
Insider Cluster
| $52.07 $53.86 | ▲ +3.44% | ▲ +1.82% | $54.87 (+5.38%) |
|
May 14, 2026
29d ago
|
144
| $52.85 $54.50 | ▲ +3.12% | ▲ +2.16% | $54.87 (+3.82%) |
|
May 6, 2026
5w ago
|
8-K
| $50.72 $51.70 | ▲ +1.93% | ▲ +0.80% | $54.87 (+8.18%) |
|
Apr 17, 2026
8w ago
|
Press Release
| $50.00 $49.38 | ▼ −1.24% | ▼ −1.79% | $54.87 (+9.74%) |
|
Apr 15, 2026
8w ago
|
Press Release
| $48.48 $49.64 | ▲ +2.39% | ▲ +1.41% | $54.87 (+13.18%) |
|
Apr 10, 2026
9w ago
|
DEFA14A
| $48.43 $49.30 | ▲ +1.80% | ▼ −1.50% | $54.87 (+13.30%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $46.37 $46.87 | ▲ +1.08% | ▼ −3.22% | $54.87 (+18.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access